Healio Coverage

May 10, 2021
1 min read

Cystic Fibrosis Awareness Month: Updates on new therapies, care delivery and more


Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In May, the cystic fibrosis community recognizes Cystic Fibrosis Awareness Month.

The Healio Editors have compiled a list of recent cystic fibrosis news in recognition of Cystic Fibrosis Awareness Month. Recent highlights include the benefits of telehealth for cystic fibrosis care delivery; a study that analyzed eligibility cystic fibrosis transmembrane conductance regulator modulators; expanded use of available therapies; and more.

Source: Adobe Stock.

Read these articles, and others, below, in no particular order.

Clinician survey highlights benefits of telehealth for cystic fibrosis care delivery

In a survey of clinicians at seven U.S. cystic fibrosis programs, telehealth for cystic fibrosis care delivery was feasible and well accepted. Read more

Underrepresented groups with cystic fibrosis less likely to be eligible for CFTR modulators

Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic fibrosis transmembrane conductance regulator modulators, according to findings published in Pediatric Pulmonology. Read more

Safety, tolerability of combination therapy sustained in children with cystic fibrosis

Combination therapy with lumacaftor/ivacaftor was safe and well tolerated for up to 120 weeks in children aged 6 to 11 years with the F508del-CFTR mutation for cystic fibrosis, according to results of an open-label, extension study. Read more

FDA approves expanded use of three cystic fibrosis therapies

The FDA approved expanded indications for three medications for the treatment of patients with cystic fibrosis with specific mutations in the CFTR gene, according to press release from Vertex Pharmaceuticals. Read more

Self-management intervention supports treatment adherence in adults with cystic fibrosis

A self-management intervention aided adults with cystic fibrosis in achieving greater adherence to inhaled medications, habit strength, lower perceived treatment burden and higher BMI over 12 months compared with usual care. Read more

Digital behavior, nutrition intervention may benefit children with cystic fibrosis

A digital behavior and nutrition intervention platform for children with cystic fibrosis was feasible and demonstrated high accessibility and satisfaction in clinical care among families and clinicians, researchers reported. Read more

Triple therapy improves FEV1 in patients with cystic fibrosis, advanced lung disease

Triple combination therapy with elexacaftor/ivacaftor/tezacaftor improved FEV1 in patients with cystic fibrosis and pre-existing advanced lung disease, according to results of a retrospective analysis. Read more